Business
Potential to prevent breast cancer relapse
Potential to prevent breast cancer relapse.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2825A\n Angle PLC\n 01 June 2021\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 1 June 2021\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n BREAKTHROUGH RESEARCH SUPPORTS POTENTIAL USE OF PARSORTIX IN PREVENTION OF RELAPSE OF BREAST CANCER PATIENTS IN REMISSION\n \n \n \n \n \n Parsortix system successfully used to harvest cancer cells \"hibernating\" in the bone marrow of breast cancer patients \n \n \n \n \n \n Parsortix enrichment of these cancer cells found to significantly enhance RNA sequencing analysis enabling the identification of clinically relevant biomarkers, which may lead to targeted treatment to eradicate these cells\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce the publication of pivotal research by Washington University School of Medicine, St. Louis, Missouri, United States into the utility of the Parsortix® system to isolate rare cancer cells present in the bone marrow (known as Disseminated Tumour Cells, or DTCs) of breast cancer patients. Analysis of DTCs in breast cancer patients may help to inform treatment decisions and potentially prevent relapse for patients in remission. \n \n \n \n \n \n Breast cancer is the most prevalent cancer in women worldwide. There is a lifetime risk of a woman developing breast cancer of some 13%. In the United States alone, there are approximately 3.7 million women alive previously diagnosed with breast cancer. Despite new treatment options and advances in patient management protocols, some 25% of women previously diagnosed with breast cancer will, often after many years of remission, relapse and die of their cancer within 20 years of diagnosis. \n \n \n \n \n \n DTCs \"hibernating\" in the bone marrow are believed to be the progenitors of distant metastatic cancer relapse when some event, currently not understood, stimulates them to re-enter the blood circulation causing distant metastatic spread of the cancer. There is a critical need to identify and molecularly characterise these rare cells, with the ambition to develop targeted treatments to prevent DTCs progressing to a metastatic site.\n \n \n \n \n \n The Parsortix...